Список проголосовавших за комментарий " Surgery Partners initiation details — Buy at The Benchmark Company; tgt $24 (18.35 +0.20)The Benchmark Company initiates SGRY with a Buy and price target of $24. Largely as a result of 2 major acquisitions, SGRY has a portfolio of 104 outpatient surgical facilities in 28 states. <strong>SGRY's approach to the ASC market emphasizes a flexible, doctor-focused (i.e., two-way) model and a local market network of physician practices and ancillary services that expand avenues for growth and support ASC utilization. With this model, same-facility rev CAGR since 2012 has been < 10%, nearly twice that of larger peers.</strong> Since its IPO in October 2015, SGRY has steadily reduced leverage to 5.4x as of 12/31/16 with a target of under 4.5x next year. The leverage was assumed for a very good reason: the acquisition of Symbion prior to the IPO that more than doubled SGRY's size and created a national footprint. The benefits of that deal are now being realized in expense and rev synergies that firm expects to play out at least through 2017."